GoAI
Get started
Agenus Inc. logo

Agenus Inc.

AGEN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$8.09

+$0.60 · +8.01%

Aug 21, 4:00 PM ET

Pre-market

$7.98

−$0.11 · -1.36%

Aug 24, 4:00 AM ET

AGEN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

76

Undervalued

Momentum

37

Weakening

Sentiment

56

Mixed

Risk resilience

27

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Garo H. Armen
Listed since
Feb 8, 2000
Employees
81

Market position

Day range

Current $8.09

52-week range

Current $8.09

Open
$7.58
Previous close
$7.49
Volume
1.52M
0.48× average
Average volume
3.19M
Average daily volume
Market cap
336.89M USD
Beta
1.55
Market reference 1
50-day average
$5.2968
+52.73% above average
200-day average
$4.0336
+100.57% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
425.27M USD
EV / EBITDA
6.84×
Earnings yield
0.12%
Free cash flow yield
-170.18%

Profitability & efficiency

Return on equity
-0.04%
Return on assets
0.05%
Return on invested capital
-34.51%

Financial health

Current ratio
0.41×
Altman Z-score
-14.26
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends65%-40%-146%-251%Gross margin, FY2021: 38.42%Gross margin, FY2022: -101.24%Gross margin, FY2023: -52.05%Gross margin, FY2024: -50.79%Gross margin, FY2025: 29.63%Operating margin, FY2021: 8.71%Operating margin, FY2022: -183.04%Operating margin, FY2023: -102.07%Operating margin, FY2024: -116.44%Operating margin, FY2025: -18.00%Net margin, FY2021: -8.09%Net margin, FY2022: -224.51%Net margin, FY2023: -157.22%Net margin, FY2024: -219.61%Net margin, FY2025: 0.10%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 38.42%. Gross margin FY2022 -101.24%. Gross margin FY2023 -52.05%. Gross margin FY2024 -50.79%. Gross margin FY2025 29.63%. Operating margin FY2021 8.71%. Operating margin FY2022 -183.04%. Operating margin FY2023 -102.07%. Operating margin FY2024 -116.44%. Operating margin FY2025 -18.00%. Net margin FY2021 -8.09%. Net margin FY2022 -224.51%. Net margin FY2023 -157.22%. Net margin FY2024 -219.61%. Net margin FY2025 0.10%.

Income trends

Revenue

114.2M USD+10.37%

Operating income

−20.56M USD+82.94%

Net income

115K USD+227.33M USD
Income trends across reported periods349.81M USD133.24M USD−83.33M USD−299.9M USDRevenue, FY2021: 295.67M USDRevenue, FY2022: 98.02M USDRevenue, FY2023: 156.31M USDRevenue, FY2024: 103.46M USDRevenue, FY2025: 114.2M USDOperating income, FY2021: 25.75M USDOperating income, FY2022: −179.43M USDOperating income, FY2023: −159.55M USDOperating income, FY2024: −120.48M USDOperating income, FY2025: −20.56M USDNet income, FY2021: −23.93M USDNet income, FY2022: −220.07M USDNet income, FY2023: −245.76M USDNet income, FY2024: −227.21M USDNet income, FY2025: 115K USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 295.67M USD. Revenue FY2022 98.02M USD. Revenue FY2023 156.31M USD. Revenue FY2024 103.46M USD. Revenue FY2025 114.2M USD. Operating income FY2021 25.75M USD. Operating income FY2022 −179.43M USD. Operating income FY2023 −159.55M USD. Operating income FY2024 −120.48M USD. Operating income FY2025 −20.56M USD. Net income FY2021 −23.93M USD. Net income FY2022 −220.07M USD. Net income FY2023 −245.76M USD. Net income FY2024 −227.21M USD. Net income FY2025 115K USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue114.2M USD103.46M USD156.31M USD98.02M USD295.67M USD
Cost of goods sold80.36M USD156.01M USD237.68M USD197.26M USD182.08M USD
Gross profit33.84M USD−52.55M USD−81.37M USD−99.24M USD113.59M USD
Research and development—155.53M USD234.57M USD—178.61M USD
Selling, general, and administrative54.39M USD71.88M USD78.74M USD81.01M USD76.36M USD
Operating expenses54.39M USD67.92M USD78.18M USD80.19M USD87.84M USD
Interest expense55.27M USD117.63M USD97.93M USD61.86M USD65.72M USD
Depreciation and amortization10M USD13.34M USD13.59M USD6.95M USD6.79M USD
Operating income−20.56M USD−120.48M USD−159.55M USD−179.43M USD25.75M USD
Net income115K USD−227.21M USD−245.76M USD−220.07M USD−23.93M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.003
FY2025
Latest fiscal-year revenue
114.2M USD
FY2025 · +10.37% year over year
Next fiscal-year EPS consensus
-0.44
FY2028 · 2 analysts
Next fiscal-year revenue consensus
137.35M USD
FY2027 · 2 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend1.56-4.69-10.95-17.2FY21FY22FY23FY24FY25FY28

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend315.43M236.37M157.32M78.26MFY21FY22FY23FY24FY25FY27FY28

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$25.00

209.02% upside
Past 12 months12-month forecastHigh $25.00Average $25.00Low $25.00

Rating distribution

11 ratings
Strong buy00%
Buy982%
Hold218%
Sell00%
Strong sell00%

Recent analyst actions

5 institutions
H.C. WainwrightupgradeNeutralBuy
JefferiesdowngradeBuyHold

AGEN news

zacks.com

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Agenus (AGEN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.05. This compares to a loss of $1 per share a year ago.

Read source
businesswire.com

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and provided an update on…

Read source
businesswire.com

Agenus to Provide Second Quarter 2026 Financial Report and Development Update

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2026 financial results before the market opens on…

Read source
zacks.com

Do Options Traders Know Something About Agenus Stock We Don't?

Investors need to pay close attention to AGEN stock based on the movements in the options market lately.

Read source
businesswire.com

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating…

Read source
zacks.com

AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot

Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.

Read source

AGEN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding AGEN

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
8.78M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
6.66M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
3.64M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.33M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.68M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
1.03M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
1.03M
Weight
0.07%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Invesco NASDAQ Future Gen 200 ETF logoInvesco NASDAQ Future Gen 200 ETFQQQS
Market value
239.58K
Weight
1.05%
AUM
22.98M USD
Expense ratio
0.20%
Price / 1D
$45.0826+1.10%

Continue in GoAI

Research AGEN

research.disclaimer